ÀÌ½ÄÆí´ë¼÷ÁÖº´(GVHD) ½ÃÀå : Áúº´ À¯Çüº°, Ä¡·á À¯Çüº°, ¿¬·É´ëº°, Åõ¿© °æ·Îº°, À¯Åë ä³Îº° - ¼¼°è ¿¹Ãø(2024-2032³â)
Graft Versus Host Disease (GVHD) Market - By Disease Type, Treatment Type, Age Group, Route of Administration, Distribution Channel - Global Forecast 2024 - 2032
»óǰÄÚµå
:
1495575
¸®¼Ä¡»ç
:
Global Market Insights Inc.
¹ßÇàÀÏ
:
2024³â 03¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 160 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
ÀÌ½ÄÆí´ë¼÷ÁÖº´(GVHD) ½ÃÀå ±Ô¸ð´Â ƯÈ÷ Ç÷¾×¾Ç¼ºÁ¾¾ç ¹× ÀÚ°¡¸é¿ªÁúȯ Ä¡·á¿¡¼ Á¶Ç÷¸ð¼¼Æ÷À̽Ä(HSCT)ÀÇ Ã¤Åà Áõ°¡·Î ÀÎÇØ 2024³âºÎÅÍ 2032³â±îÁö ¿¬Æò±Õ 8.1%ÀÇ ¼ºÀå·üÀ» ±â·ÏÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.
¹Ì±¹ ±¹¸³º¸°Ç¿ø(National Institute of Health)¿¡ µû¸£¸é, ¿¬°£ ¾à 5¸¸ °ÇÀÇ Áٱ⼼Æ÷ À̽ÄÀÌ ÀÌ·ç¾îÁö°í ÀÖÀ¸¸ç, ¿¬°£ ¼ºÀå·üÀº 10%¿¡¼ 15%¿¡ ´ÞÇÕ´Ï´Ù. Á¶Ç÷¸ð¼¼Æ÷ À̽ÄÀº ¿©ÀüÈ÷ ´Ù¾çÇÑ Áúº´¿¡ ´ëÇÑ Áß¿äÇÑ Ä¡·á¹ýÀ̱⠶§¹®¿¡ GVHDÀÇ ¹ß»ý·üÀº ±×¿¡ µû¶ó Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÇ·á±â¼ú°ú À̽ļúÀÇ ±Þ¼ÓÇÑ ¹ßÀüÀ¸·Î ÀÌ½Ä È¯ÀÚÀÇ »ýÁ¸À²ÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù.
ÀÇ·áÁø°ú ȯÀÚµéÀÇ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó GVHD °ü¸®¿¡¼ Á¶±â ¹ß°ß°ú ½Å¼ÓÇÑ °³ÀÔÀÇ Á߿伺ÀÌ ´õ¿í ºÎ°¢µÇ°í ÀÖ½À´Ï´Ù. Àû½Ã¿¡ Áø´ÜÇϸé ÀûÀýÇÑ Ä¡·á Àü·«À» ½ÃÀÛÇÒ ¼ö ÀÖ¾î GVHDÀÇ ÁßÁõµµ¸¦ ÁÙÀ̰í ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. À¯È¿¼º°ú ¾ÈÀü¼ºÀ» °³¼±ÇÑ »õ·Î¿î Ä¡·áÁ¦ °³¹ß¿¡ ÁßÁ¡À» µÐ ¿¬±¸°³¹ß Ȱµ¿ÀÌ ÁøÇàµÇ°í ÀÖ´Â °Íµµ ½ÃÀå È®´ë¸¦ ´õ¿í ÃËÁøÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.
GVHD »ê¾÷Àº Áúº´ À¯Çü, Ä¡·á À¯Çü, ¿¬·É´ë, Åõ¿© °æ·Î, À¯Åë ä³Î, Áö¿ªÀ¸·Î ±¸ºÐµË´Ï´Ù.
Ä¡·á À¯Çüº°·Î´Â ºÎ½ÅÇÇÁú ½ºÅ×·ÎÀÌµå ½ÃÀå ±Ô¸ð´Â °·ÂÇÑ Ç׿°Áõ ¹× ¸é¿ª¾ïÁ¦ È¿°ú·Î ÀÎÇØ 2032³â±îÁö 7.8%ÀÇ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ºÎ½ÅÇÇÁú ½ºÅ×·ÎÀ̵å´Â °æ±¸¿ë, Á¤¸ÆÁÖ»ç, ±¹¼Ò¿ë µî ´Ù¾çÇÑ Á¦ÇüÀ¸·Î ³Î¸® »ç¿ëµÇ°í ÀÖÀ¸¸ç, GVHDÀÇ ÁßÁõµµ ¹× ¹ßÇö ºÎÀ§¿¡ µû¸¥ Ä¡·áÀû Á¢±ÙÀ» °¡´ÉÇÏ°Ô ÇÏ´Â À¯¿¬¼ºÀ» Á¦°øÇÕ´Ï´Ù.
Åõ¿© °æ·Î Ãø¸é¿¡¼ ÀÌ½ÄÆí´ë¼÷ÁÖº´ ½ÃÀåÀÇ °æ±¸¿ë ÀǾàǰ ºÎ¹®Àº 2024-2032³â 8.4%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. °æ±¸¿ë ÀǾàǰÀº ȯÀÚ¿¡°Ô ÆíÀǼº°ú Åõ¾àÀÇ ¿ëÀ̼ºÀ» Á¦°øÇÏ¿© ÀÓ»ó ȯ°æ ¹Û¿¡¼ ÀÚ°¡ °ü¸®¸¦ º¸ÀåÇϰí Ä¡·á ¿ä¹ý Áؼö¸¦ ÃËÁøÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ÆíÀǼºÀº ȯÀÚÀÇ ¼øÀÀµµ¸¦ ³ô¿© Ä¡·á °á°ú¿Í Àü¹ÝÀûÀÎ »îÀÇ Áú Çâ»óÀ¸·Î À̾îÁý´Ï´Ù.
¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÀÌ½ÄÆí´ë¼÷ÁÖº´ »ê¾÷Àº 2024³âºÎÅÍ 2032³â±îÁö ¿¬Æò±Õ 8.5%ÀÇ °ý¸ñÇÒ ¸¸ÇÑ ¼ºÀåÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ´Â Á¶Ç÷¸ð¼¼Æ÷ À̽Ä(HSCT)ÀÇ ¹ßº´·üÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, ƯÈ÷ ÀÇ·á ÀÎÇÁ¶ó°¡ Àß °®Ãß¾îÁ® ÀÖ°í ÀÌ½Ä ¼ºñ½º¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ °³¼±µÈ ±¹°¡µé¿¡¼ ±× ºñÀ²ÀÌ Áõ°¡Çϰí Àֱ⠶§¹®ÀÔ´Ï´Ù. ÇöÁö ÀÇ·á±â°ü, Á¦¾à»ç, ¿¬±¸±â°ü °£ÀÇ Çù·ÂÀÌ °ÈµÇ¸é¼ ÀÓ»óÀû Çʿ信 ¸Â´Â »õ·Î¿î GVHD Ä¡·áÁ¦ÀÇ ½ÃÀå °³¹ßÀÌ ÃËÁøµÇ°í ÀÖÀ¸¸ç, ÀÌ´Â ÀÌ Áö¿ªÀÇ ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå ¾÷°è ÀλçÀÌÆ®
- »ýÅÂ°è ºÐ¼®
- ¾÷°è¿¡ ´ëÇÑ ¿µÇâ¿äÀÎ
- ¼ºÀå ÃËÁø¿äÀÎ
- Ç÷¾×Áúȯ À¯º´·ü Áõ°¡
- ÀÌ½Ä ±â¼úÀÇ Áøº¸
- ¿¬±¸°³¹ß ÅõÀÚ Áõ°¡
- Ä¡·áÁ¦ ÆÄÀÌÇÁ¶óÀÎ Áõ°¡
- ¾÷°èÀÇ ÀáÀçÀû ¸®½ºÅ©¿Í °úÁ¦
- ³ôÀº Ä¡·áºñ
- ¾ö°ÝÇÑ ±ÔÁ¦ °úÁ¦
- ÇÕº´ÁõÀ̳ª Àç¹ß ¸®½ºÅ©
- ¼ºÀå °¡´É¼º ºÐ¼®
- ÆÄÀÌÇÁ¶óÀÎ ºÐ¼®
- ±ÔÁ¦ »óȲ
- Porters ºÐ¼®
- PESTEL ºÐ¼®
Á¦4Àå °æÀï »óȲ
- ¼Ò°³
- ±â¾÷ ¸ÅÆ®¸¯½º ºÐ¼®
- ÁÖ¿ä ½ÃÀå ±â¾÷ °æÀï ºÐ¼®
- °æÀï Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º
- Àü·« ´ë½Ãº¸µå
Á¦5Àå ½ÃÀå ÃßÁ¤°ú ¿¹Ãø : Áúȯ À¯Çüº°, 2021-2032³â
- ÁÖ¿ä µ¿Çâ
- ±Þ¼º ÀÌ½ÄÆí´ë¼÷ÁÖº´(aGVDH)
- ¸¸¼º ÀÌ½ÄÆí´ë¼÷ÁÖº´(cGVDH)
Á¦6Àå ½ÃÀå ÃßÁ¤°ú ¿¹Ãø : Ä¡·á À¯Çüº°, 2021-2032³â
- ÁÖ¿ä µ¿Çâ
- ´ÜŬ·ÐÇ×ü
- mTOR ¾ïÁ¦Á¦
- Ƽ·Î½Å Ű³ª¾ÆÁ¦ ¾ïÁ¦Á¦
- ¸é¿ª¾ïÁ¦Á¦
- ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å
- ±âŸ Ä¡·á
Á¦7Àå ½ÃÀå ÃßÁ¤°ú ¿¹Ãø : ¿¬·ÉÃþº°, 2021-2032³â
- ÁÖ¿ä µ¿Çâ
- 20¼¼ ¹Ì¸¸
- 21-50¼¼
- 51¼¼ ÀÌ»ó
Á¦8Àå ½ÃÀå ÃßÁ¤°ú ¿¹Ãø : Åõ¿© °æ·Îº°, 2021-2032³â
- ÁÖ¿ä µ¿Çâ
- °æ±¸
- Á¤¸Æ³»
- ±¹¼Ò
Á¦9Àå ½ÃÀå ÃßÁ¤°ú ¿¹Ãø : À¯Åë ä³Îº°, 2021-2032³â
- ÁÖ¿ä µ¿Çâ
- º´¿ø ¾à±¹
- ¼Ò¸Å ¾à±¹
- ¿Â¶óÀÎ ¾à±¹
Á¦10Àå ½ÃÀå ÃßÁ¤°ú ¿¹Ãø : Áö¿ªº°, 2021-2032³â
- ÁÖ¿ä µ¿Çâ : Áö¿ªº°
- ºÏ¹Ì
- À¯·´
- µ¶ÀÏ
- ¿µ±¹
- ÇÁ¶û½º
- ½ºÆäÀÎ
- ÀÌÅ»¸®¾Æ
- ±âŸ À¯·´
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- ÀϺ»
- Áß±¹
- Àεµ
- È£ÁÖ
- ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
- ¶óƾ¾Æ¸Þ¸®Ä«
- ºê¶óÁú
- ¸ß½ÃÄÚ
- ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- ³²¾ÆÇÁ¸®Ä«°øÈ±¹
- »ç¿ìµð¾Æ¶óºñ¾Æ
- ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
Á¦11Àå ±â¾÷ °³¿ä
- Astellas Pharma Inc.
- Bristol Myers Squibb
- ElsaLys Biotech SA
- Incyte Corporation
- Johnson & Johnson Services, Inc.
- Kiadis Pharma
- Mallinckrodt Pharmaceuticals
- Merck & Co., Inc.
- Mesoblast Ltd
- Neovii Pharmaceuticals AG
- Novartis AG
- Pfizer Inc.
- Sanofi
- Soligenix
ksm
¿µ¹® ¸ñÂ÷
Graft versus host disease (GVHD) market size is estimated to register 8.1% CAGR between 2024 to 2032, driven by the increasing adoption of hematopoietic stem cell transplantation (HSCT) procedures, particularly in the treatment of hematologic malignancies and autoimmune disorders. As per National Institute of Health, approximately 50,000 stem cell transplants are conducted annually, experiencing an annual growth rate ranging between 10% to 15%. As HSCT remains a crucial treatment modality for various diseases, the incidence of GVHD is expected to rise correspondingly. Rapid advancements in medical technology and transplant procedures have led to improved survival rates among transplant recipients.
Increased awareness among healthcare providers and patients is further outlining the importance of early detection and prompt intervention in GVHD management. Timely diagnosis allows the initiation of appropriate treatment strategies, thereby reducing the severity of GVHD and improving patient outcomes. The ongoing R&D activities focused on the development of novel therapeutics with improved efficacy and safety profiles will further propel the market expansion.
The GVHD industry is segmented into disease type, treatment type, age group, route of administration, distribution channel and region.
Based on treatment type, the market size from the corticosteroids segment is anticipated to witness 7.8% growth rate through 2032, due to their potent anti-inflammatory and immunosuppressive properties. Corticosteroids are widely available in various formulations, including oral, intravenous, and topical preparations for offering flexibility in administration and enabling tailored treatment approaches based on the severity and site of GVHD manifestations.
With regards to route of administration, the oral segment in the graft versus host diseases market is anticipated to observe 8.4% CAGR during 2024-2032. Oral medications offer patients convenience and ease of administration ensuring self-management outside of clinical settings and promoting adherence to treatment regimens. This accessibility is enhancing patient compliance while leading to improved treatment outcomes and overall quality of life.
Asia Pacific graft versus host disease industry will record impressive growth at 8.5% CAGR over 2024-2032. This can be attributed to the rising incidence of hematopoietic stem cell transplantation (HSCT) procedures, particularly in countries with growing healthcare infrastructure and improved access to transplant services. Rising collaborations between local healthcare institutions, pharmaceutical companies, and research organizations is fostering the development of novel GVHD therapies tailored to the clinical needs, further stimulating the regional market growth.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360 degree synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increasing prevalence of hematological disorders
- 3.2.1.2 Advancements in transplantation techniques
- 3.2.1.3 Rising investments in research and development
- 3.2.1.4 Growing pipeline of therapeutic agents
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 High treatment cost
- 3.2.2.2 Stringent regulatory challenges
- 3.2.2.3 Risk of complications and relapse
- 3.3 Growth potential analysis
- 3.4 Pipeline analysis
- 3.5 Regulatory landscape
- 3.6 Porter's analysis
- 3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company matrix analysis
- 4.3 Competitive analysis of major market players
- 4.4 Competitive positioning matrix
- 4.5 Strategic dashboard
Chapter 5 Market Estimates and Forecast, By Disease Type, 2021 - 2032 ($ Million)
- 5.1 Key trends
- 5.2 Acute graft versus host disease (aGVDH)
- 5.3 Chronic graft versus host disease (cGVDH)
Chapter 6 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Million)
- 6.1 Key trends
- 6.2 Monoclonal antibodies
- 6.3 mTOR inhibitors
- 6.4 Tyrosine kinase inhibitors
- 6.5 Immunosuppressants
- 6.6 Corticosteroids
- 6.7 Other treatment types
Chapter 7 Market Estimates and Forecast, By Age Group, 2021 - 2032 ($ Million)
- 7.1 Key trends
- 7.2 < 20 years
- 7.3 21-50 years
- 7.4 51 years and above
Chapter 8 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Million)
- 8.1 Key trends
- 8.2 Oral
- 8.3 Intravenous
- 8.4 Topical
Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Million)
- 9.1 Key trends
- 9.2 Hospital pharmacies
- 9.3 Retail pharmacies
- 9.4 Online pharmacies
Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Million)
- 10.1 Key trends, by region
- 10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
- 10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Spain
- 10.3.5 Italy
- 10.3.6 Rest of Europe
- 10.4 Asia Pacific
- 10.4.1 Japan
- 10.4.2 China
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 Rest of Asia Pacific
- 10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Rest of Latin America
- 10.6 Middle East and Africa
- 10.6.1 South Africa
- 10.6.2 Saudi Arabia
- 10.6.3 Rest of Middle East and Africa
Chapter 11 Company Profiles
- 11.1 Astellas Pharma Inc.
- 11.2 Bristol Myers Squibb
- 11.3 ElsaLys Biotech SA
- 11.4 Incyte Corporation
- 11.5 Johnson & Johnson Services, Inc.
- 11.6 Kiadis Pharma
- 11.7 Mallinckrodt Pharmaceuticals
- 11.8 Merck & Co., Inc.
- 11.9 Mesoblast Ltd
- 11.10 Neovii Pharmaceuticals AG
- 11.11 Novartis AG
- 11.12 Pfizer Inc.
- 11.13 Sanofi
- 11.14 Soligenix
°ü·ÃÀÚ·á